← Leaderboards
Michele Kong
University Of Alabama At Birmingham
$4,039,938
Attributed
$4,039,938
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $734.5K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,039,938 · 2
By mechanism
R01$3,324,945 · 1
K08$714,993 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Kai Jiao$7,147,323
- Alan Thevenet N. Tita$31,628,801
- David A Calhoun$6,925,470
- Waldemar A. Carlo$27,528,882
- Stephen Barnes$26,295,575
Others in their field
Top investigators on “Virus Diseases”
- Barton F Haynes · Duke University$305,832,186
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Lawrence Corey · Fred Hutchinson Cancer Center$271,990,515
- Richard Webby · St. Jude Children'S Research Hospital$264,105,723
- David Heimbrook · Leidos Biomedical Research, Inc.$262,417,885
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$252,117,999
Research focus
Virus DiseasesPeptide HydrolasesSeverity Of IllnessViralVirus ReplicationViral Load ResultGelatinase BPathway InteractionsLung DiseasesTissue Inhibitor Of Metalloproteinase-1Respiratory Syncytial Virus InfectionsPhysiciansRespiratory Syncytial VirusRespiratory FailureChildhoodEndotrachealBronchiolitisInflammatoryLeukocyte ElastaseLungChildMacrolidesPneumoniaPulmonary Inflammation
Grant awards (10)
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children$629,055
R01 · FY2025 · HD · contact PI
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children$645,902
R01 · FY2024 · HD · contact PI
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children$659,128
R01 · FY2023 · HD · contact PI
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children$656,356
R01 · FY2022 · HD · contact PI
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children$734,504
R01 · FY2021 · HD · contact PI
Matrix Metalloproteinase Driven Lung Inflammation in RSV disease$159,435
K08 · FY2018 · HL · contact PI
Matrix Metalloproteinase Driven Lung Inflammation in RSV disease$159,435
K08 · FY2017 · HL · contact PI
Matrix Metalloproteinase Driven Lung Inflammation in RSV disease$159,435
K08 · FY2016 · HL · contact PI
Matrix Metalloproteinase Driven Lung Inflammation in RSV disease$118,344
K08 · FY2015 · HL · contact PI
Matrix Metalloproteinase Driven Lung Inflammation in RSV disease$118,344
K08 · FY2014 · HL · contact PI